Drug-Resistant Superbugs, Multi-drug Resistant Organisms: MRSA, VRE, Clostridium difficile, and CRE (by LabCE)

2.5 P.A.C.E. contact hour(s)

(based on 437 customer ratings)

Authors: Carolyn M. Law, PhD, MT(AMT); Catherine Dragoni, MT(ASCP)SM
Co-author: Judi Bennett, MT, BSM

Course provided by LabCE.

In light of the recent death of a Nevada woman infected with carbapenem-resistant Enterobacteriaceae (CRE), we wonder how prepared our laboratory professionals are for the challenges that may lie ahead...



To aid in the continued education about CRE and other multi-drug resistant microbes, we're republishing our Multi-drug Resistant Organisms: MRSA, VRE, Clostridium difficile, and CRE course. New information and updates have been added to address the potential of increased CRE infections.



Multiple drug resistant organisms (MDROs) are a serious problem facing healthcare and the general public. This course details the clinical significance, risk factors, and laboratory detection of these multi-drug resistant organisms: methicillin resistant Staphylococcus aureus, vancomycin resistant Enterococcus species, Clostridium difficile, and carbapenem-resistant Enterobacteriaceae.

See more courses in: Microbiology

Continuing Education Credits

P.A.C.E.® Contact Hours (acceptable for AMT, ASCP, and state recertification): 2.5 hour(s)
Course number 578-013-17, approved through 2/28/2019
Florida Board of Clinical Laboratory Personnel Credit Hours - General (Microbiology/Mycology/Parasitology): 2.5 hour(s)
Course number 20-565993, approved through 9/1/2018

Objectives

  • Identify the virulence factors that are expressed by drug resistant strains of Staphylococcus aureus, Clostridium difficile, Enterococcus faecium and faecalis, and carbapenem-resistant Enterobacteriaceae.
  • List the risk factors and clinical syndromes that are associated with these drug resistant organisms.
  • Describe the recommended laboratory procedures involved in screening for and detecting drug-resistant organisms.
  • Name the drugs that are currently available for treatment of these infections and describe the proper treatment protocols.

Customer Ratings

(based on 437 customer ratings)

Course Outline

  • Introduction
      • Methicillin Resistant Staphylococcus aureus
      • Vancomycin Resistant Enterococci
      • Clostridium difficile
      • Carbapenem-Resistant Enterobacteriaceae
  • Staphylococcus aureus
      • Staphylococcus aureus
      • S. aureus Virulence Factors
      • Clinical significance of S. aureus
      • Beta-lactam antibiotics and S. aureus
  • MRSA
      • Beta-lactams and Methicillin Resistant Staphylococcus aureus
      • Healthcare (Hospital)-Associated MRSA (HA-MRSA) versus Community-Associated MRSA (CA-MRSA)
      • Risk Factors
  • Laboratory Diagnosis of MRSA
      • Laboratory Identification of S. aureus
      • Screening Cultures for MRSA
    • Susceptibility Testing of Isolates
      • Susceptibility Testing
      • Selection of Drugs for Testing
      • Interpretation of Oxacillin Broth Dilution Tests.
      • Interpretation of Oxacillin and Cefoxitin Disk Diffusion Tests
      • Detection of Oxacillin Resistance
  • MRSA Treatment/Vancomycin Resistance in S. aureus
      • MRSA Treatment/Vancomycin Resistance
      • VISA and VRSA
    • Testing for Vancomycin Susceptibility
      • Testing for Vancomycin Susceptibility
  • Future Perspectives: MRSA
      • Future Perspectives
      • Future Perspectives, continued
      • Future Perspectives, continued
  • Enterococcus
      • Enterococci
      • Risk Factors and Resistance
  • Vancomycin Resistant Enterococci
      • Vancomycin-Resistant Enterococci (VRE) Phenotypes
  • Laboratory Diagnosis of VRE
      • Identification of Enterococcus Species From Clinical Cultures
      • Screening Cultures for Vancomycin-Resistant Enterococci (VRE)
      • Susceptibility Testing of Enterococci
      • Detecting Vancomycin Resistance
      • High Level Aminoglycoside Resistance (HLAR) Screening
  • Treatment of Resistant Enterococci
      • Newer antibiotics for Treatment of Resistant Enterococci
  • Clostridium Species
      • Clostridium Species
  • Clostridium difficile
      • Clostridium difficile
      • C. difficile Toxin A and Toxin B
      • Pathogenisis of C. Difficile-Associated Diarrhea
      • Risk factors for C. difficile Infection
      • C. difficile-associated Diarrhea (CDAD)
      • Strain BI/NAP1/027
  • Laboratory Diagnosis of CDAD
      • Laboratory Detection of C. difficile
      • Stool Culture
      • Cell Cytotoxicity Neutralization Assay (CCNA)
      • Enzyme Immunoassay Methods
      • Glutamate Dehydrogenase (GDH) Antigen Assays
      • Molecular Methods
  • Treatment of C. difficile Infection
      • Treatment of C. difficile Infection (CDI) and C. difficile Associated Disease (CDAD)
      • Disinfection & Control of C. difficile Infection
  • Future perspectives
      • Future perspectives: CDI/CDAD
  • Carbapenem-Resistant Enterobacteriaceae
      • Enterobacteriaceae and Spectrum of Disease
      • CRE Defined and Risk Factors
      • Mechanisms of Resistance
      • Carbapenemase-Producing Enterobacteriaceae
  • Laboratory Diagnosis of CRE
      • Detection, Identification, and Susceptibility Testing of CRE
      • Summary: CRE Versus CP-CRE
  • Treatment and Control of CRE
      • Treatment of CRE
      • Control of CRE
      • CRE Screening
  • Future Perspective: CRE
      • Future Perspecitves: CRE
  • References
      • References

Additional Information

Level of instruction: Intermediate
Intended audience: Medical laboratory scientists, medical technologists, and technicians, This course is also appropriate for clinical laboratory science students and pathology residents.
Author information: Carolyn M. Law, PhD, MT(AMT) is the CEO of Celtic Labs Diagnostic Microbiology Services in Trinidad. She holds a PhD in Microbiology from National University of Ireland, Maynooth.
Catherine Dragoni, MT(ASCP)SM received her BS degree in medical technology from the State University of New York, Upstate Medical Center, Syracuse. She began her career as a bench microbiologist at Maine Medical Center, Portland, Maine. Currently she is the Assistant Chief Technologist of Microbiology and Molecular Pathology at NorDx Laboratories, Scarborough, Maine.
Co-author information: Judi Bennett, MT, BSM is currently a Program Director for MediaLab, Inc. in Lawrenceville, Georgia. She has over 30 years of medical laboratory experience in an acute care hospital setting as a laboratory manager, senior clinical applications specialist, point-of-care coordinator, microbiology supervisor, and generalist technologist. Judi has experience speaking at various professional conferences and is the author of numerous peer-reviewed publications.  
Course description: Multiple drug resistant organisms (MDROs) are a serious problem facing healthcare and the general public. This course details the clinical significance, risk factors, and laboratory detection of these multi-drug resistant organisms: methicillin resistant Staphylococcus aureus, vancomycin resistant Enterococcus species, Clostridium difficile, and carbapenem-resistant Enterobacteriaceae. Future perspectives are also discussed.    

How to Subscribe
MLS & MLT Comprehensive CE Package (by LabCE)
Package of 99 online courses$95
Add to cart
Single online course$25
Add to cart
  • Order for instant access through any computer, any browser.
  • No shipping, faxing, or waiting for certificates.
  • Print or save your certificate of completion as soon as you've completed the course.
  • You'll have 90 days to complete your purchased courses.
Course provided by LabCE.
C diff on BAP_edit


C diff_gram


C. diff on CCFA_edit


Staph



 
ASCLS CE's design and platform are provided by MediaLab, Inc.